About Zai Lab
Zai Lab is a company based in Shanghai (China) founded in 2013. Zai Lab has raised $160 million across 3 funding rounds from investors including Kleiner Perkins, Orbimed and Qiming Venture Partners. The company has 1,870 employees as of December 31, 2024. Zai Lab offers products and services including Transformative Medicines and Innovative Therapies. Zai Lab operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Shanghai, China
- Employees 1870 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Zai Lab Ltd.
-
Annual Revenue
$400.44 M (USD)49.09as on Dec 31, 2024
-
Net Profit
-$258.8 M (USD)23.42as on Dec 31, 2024
-
EBITDA
-$262.67 M (USD)27.27as on Dec 31, 2024
-
Total Equity Funding
$160 M (USD)
in 3 rounds
-
Latest Funding Round
$30 M (USD), Series C
Jun 30, 2017
-
Investors
Kleiner Perkins
& 8 more
-
Employee Count
1870
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Zai Lab
Zai Lab is a publicly listed company on the HKEX with ticker symbol 9688 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Zai Lab
Zai Lab offers a comprehensive portfolio of products and services, including Transformative Medicines and Innovative Therapies.
Develops treatments for oncology and infectious diseases through research.
Focuses on immunology and neuroscience solutions via clinical pipelines.
People of Zai Lab
Unlock access to complete
Unlock access to complete
Leadership Team
36 people
Software Development Team
8 people
Human Resources and Administration
8 people
Operations Team
8 people
Finance and Accounting
5 people
Senior Team
4 people
Sales and Marketing
4 people
Product Management Team
3 people
Unlock access to complete
Funding Insights of Zai Lab
Zai Lab has successfully raised a total of $160M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Zai Lab
Zai Lab has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Orbimed and Qiming Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Venture capital and private equity firm
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked |
Investor details for Zai Lab
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Zai Lab
Investment portfolio details for Zai Lab
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Zai Lab
Detailed financials for Zai Lab
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zai Lab Comparisons
Peer comparison for Zai Lab
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Zai Lab
Zai Lab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Zai Lab
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zai Lab
Complete news archive for Zai Lab
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zai Lab
Zai Lab was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Zai Lab is headquartered in Shanghai, China.
Zai Lab is a funded company, having raised a total of $160M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Zai Lab is 1,870.
Annual revenue of Zai Lab is $400.44M as on Dec 31, 2024.
Zai Lab was founded in 2013 in Shanghai, China, within the biotechnology sector. Innovative drugs targeting anti-cancer and anti-inflammatory conditions are developed, including antibody-based therapies for hepatocellular carcinoma and lung cancer. Additional products address asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, and graft versus host disease. Operations center on research and development of these therapeutic solutions in the pharmaceutical industry.
Zai Lab's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Zai Lab offers Transformative Medicines and Innovative Therapies.
Yes, Zai Lab is publicly traded on HKEX under the ticker symbol 9688.
Zai Lab has 9 investors. Key investors include Kleiner Perkins, Orbimed, Qiming Venture Partners, Vivo Capital, and Rock Springs Capital.
The ticker symbol of Zai Lab is 9688 on HKEX.